JP2016516049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516049A5 JP2016516049A5 JP2016502968A JP2016502968A JP2016516049A5 JP 2016516049 A5 JP2016516049 A5 JP 2016516049A5 JP 2016502968 A JP2016502968 A JP 2016502968A JP 2016502968 A JP2016502968 A JP 2016502968A JP 2016516049 A5 JP2016516049 A5 JP 2016516049A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- bispecific binding
- component
- antibody
- dimerization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 66
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 238000006471 dimerization reaction Methods 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 102000037865 fusion proteins Human genes 0.000 claims description 28
- 108020001507 fusion proteins Proteins 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 27
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 239000000710 homodimer Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 11
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims description 6
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 241000235058 Komagataella pastoris Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims 6
- 239000012642 immune effector Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- -1 each 5 ′ to 3 ′ Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791600P | 2013-03-15 | 2013-03-15 | |
| US61/791,600 | 2013-03-15 | ||
| PCT/US2014/029041 WO2014144573A2 (en) | 2013-03-15 | 2014-03-14 | Multimerization technologies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516049A JP2016516049A (ja) | 2016-06-02 |
| JP2016516049A5 true JP2016516049A5 (enExample) | 2017-04-13 |
| JP6480907B2 JP6480907B2 (ja) | 2019-03-13 |
Family
ID=51538343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502968A Active JP6480907B2 (ja) | 2013-03-15 | 2014-03-14 | 多量体化技術 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9802995B2 (enExample) |
| EP (1) | EP2968547B1 (enExample) |
| JP (1) | JP6480907B2 (enExample) |
| KR (1) | KR102090356B1 (enExample) |
| CN (1) | CN105530959B (enExample) |
| AU (1) | AU2014228962B2 (enExample) |
| BR (1) | BR112015022978A8 (enExample) |
| CA (1) | CA2902561C (enExample) |
| RU (1) | RU2714733C2 (enExample) |
| WO (1) | WO2014144573A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902561C (en) | 2013-03-15 | 2022-08-02 | Memorial Sloan-Kettering Cancer Center | Multimerization technologies |
| AU2014228772B2 (en) * | 2013-03-15 | 2019-02-28 | Memorial Sloan Kettering Cancer Center | High affinity anti-GD2 antibodies |
| IL319092A (en) | 2013-05-06 | 2025-04-01 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
| US10370776B2 (en) * | 2013-09-25 | 2019-08-06 | Idea Orchard, Llc | Antibody like protein |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| WO2017055385A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| HK1253049A1 (zh) | 2015-11-12 | 2019-06-06 | Seagen Inc. | 糖基相互作用化合物及其使用方法 |
| CA3038504A1 (en) * | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| US11401330B2 (en) * | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| TWI667253B (zh) * | 2016-12-30 | 2019-08-01 | 博晟生醫股份有限公司 | 重組多肽、核酸分子及其組合物以及製造、使用之方法 |
| US11046768B2 (en) * | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| US20200231700A1 (en) * | 2017-02-20 | 2020-07-23 | Dragonfly Therapeutics, Inc. | Proteins binding gd2, nkg2d and cd16 |
| KR102653141B1 (ko) | 2017-03-03 | 2024-04-01 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
| JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| JPWO2020071554A1 (ja) * | 2018-10-05 | 2021-09-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| KR20210128399A (ko) * | 2019-02-20 | 2021-10-26 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 암-표적화되고, 바이러스-암호화된, 조절 가능한 t 세포 (catvert) 또는 nk 세포 (catvern) 링커 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2023532973A (ja) * | 2020-07-03 | 2023-08-01 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 多官能直交タンパク質キメラ |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
| WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| CA3255619A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS |
| KR20250054843A (ko) * | 2022-07-25 | 2025-04-23 | 바이로넥시스 바이오테라퓨틱스 인코포레이티드 | 아데노-관련 바이러스 벡터 및 전이 위험을 감소시키고 치료 및 예방하기 위한 이들의 사용 방법 |
| CU20230043A7 (es) * | 2023-09-08 | 2025-04-04 | Ct Inmunologia Molecular | Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| GB0230202D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
| EP1293514B1 (en) * | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| US20070298041A1 (en) * | 2002-06-28 | 2007-12-27 | Tomlinson Ian M | Ligands That Enhance Endogenous Compounds |
| EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| WO2006107617A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| WO2006009901A2 (en) * | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2011268110B2 (en) * | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| CA2902561C (en) | 2013-03-15 | 2022-08-02 | Memorial Sloan-Kettering Cancer Center | Multimerization technologies |
-
2014
- 2014-03-14 CA CA2902561A patent/CA2902561C/en active Active
- 2014-03-14 EP EP14765530.2A patent/EP2968547B1/en active Active
- 2014-03-14 CN CN201480028543.2A patent/CN105530959B/zh active Active
- 2014-03-14 JP JP2016502968A patent/JP6480907B2/ja active Active
- 2014-03-14 RU RU2015143166A patent/RU2714733C2/ru active
- 2014-03-14 WO PCT/US2014/029041 patent/WO2014144573A2/en not_active Ceased
- 2014-03-14 KR KR1020157029267A patent/KR102090356B1/ko active Active
- 2014-03-14 AU AU2014228962A patent/AU2014228962B2/en active Active
- 2014-03-14 US US14/776,267 patent/US9802995B2/en active Active
- 2014-03-14 BR BR112015022978A patent/BR112015022978A8/pt active Search and Examination
-
2017
- 2017-09-26 US US15/715,499 patent/US20180251503A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516049A5 (enExample) | ||
| US20240174745A1 (en) | Antibody Constructs for CLDN18.2 and CD3 | |
| JP7014843B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| RU2015143166A (ru) | Технологии мультимеризации | |
| Root et al. | Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer | |
| JP2018519296A5 (enExample) | ||
| US10640570B2 (en) | Chimeric antigen receptors, compositions, and methods | |
| Malm et al. | Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin‐binding domain allows for affinity purification and in vivo half‐life extension | |
| JP2021502063A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2019528077A5 (enExample) | ||
| CA2863944A1 (en) | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds | |
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| JP2018529363A5 (enExample) | ||
| JP2016525551A5 (enExample) | ||
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| HRP20251060T1 (hr) | Samosklapajuće proteinske nanostrukture koje prikazuju f proteine paramiksovirusa i/ili pneumovirusa i njihova uporaba | |
| JP2018524326A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| CN109071662A (zh) | 双特异性t细胞接合抗体构建体 | |
| JP2017525354A5 (enExample) | ||
| JP2019531697A5 (enExample) | ||
| HK1207575A1 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| JP2013531470A5 (enExample) | ||
| JP2013529084A5 (enExample) |